PDF(Sci-hub)
Abstract：
Treatment for telangiectasia macularis eruptiva perstans (TMEP) is often challenging due to lack of an established first-line therapy and as such is primarily focused on symptomatic relief. Omalizumab shows promise as a potential therapy for mast cell disorders; however, its efficacy in TMEP is yet to be established. This case describes a 72-year-old woman with chronic refractory TMEP achieving symptomatic remission within 4 months of commencing omalizumab therapy.
摘要：
由于缺乏既定的一线治疗，黄斑毛细血管扩张症（TMEP）的治疗通常具有挑战性，因此主要集中在症状缓解上。奥马珠单抗显示出有望作为肥大细胞疾病的潜在疗法;然而，其在TMEP中的疗效尚待确定。该病例描述了一名72岁女性，患有慢性难治性TMEP，在开始奥马珠单抗治疗4个月内达到症状缓解。
